despit
recent
progress
gsk
rt
malaria
vaccin
remain
desper
need
effici
malaria
vaccin
use
repetit
antigen
display
technolog
display
malaria
specif
b
cell
cell
epitop
effort
design
vaccin
plasmodium
falciparum
malaria
protein
sequenc
assembl
nanoparticl
induc
strong
longliv
protect
immun
respons
infect
parasit
confid
clinic
trial
develop
vaccin
candid
show
good
protect
control
human
malaria
infect
trial
malaria
afflict
million
peopl
worldwid
kill
peopl
mostli
children
http
yet
highli
effect
malaria
vaccin
adult
children
still
miss
develop
vaccin
pathogen
typic
escap
immun
surveil
p
falciparum
proven
difficult
bioengin
challeng
parasit
evolv
way
present
import
function
protein
ie
one
may
involv
host
cell
recognit
invas
manner
immunogen
quagmir
vaccinologist
identifi
manufactur
protein
epitop
present
correct
conform
overcom
immunolog
toler
provok
function
growth
inhibitori
immun
effect
recombin
malaria
vaccin
candid
date
rt
vaccin
base
circumsporozoit
protein
csp
p
falciparum
sporozoit
parasit
stage
mosquito
inject
human
yet
clinic
trial
larg
phase
field
challeng
financi
compet
interest
disclosur
p
burkhard
founder
coowner
ceo
alphao
peptid
ag
compani
involv
nanoparticl
vaccin
design
also
research
professor
univers
connecticut
along
de
lanar
receiv
nih
fund
malaria
vaccin
project
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
studi
effect
believ
final
realiz
csp
true
potenti
requir
epitop
optim
display
formul
elicit
respons
even
strongli
immunogen
ultim
highli
protect
recent
year
materi
welldefin
submicromet
structur
attract
interest
biomed
industri
nanos
lipidor
polymerbas
particl
design
improv
drug
deliveri
liposom
virosom
viruslik
particl
vlp
polymer
bead
use
vaccin
protein
separ
even
blood
cell
substitut
synthet
peptid
alon
use
vaccin
candid
usual
suffici
immunogen
adjuv
need
includ
enhanc
immunogen
howev
number
adjuv
use
human
limit
critic
need
exist
novel
deliveri
vehicl
capabl
elicit
suffici
strong
humor
cellular
immun
respons
crucial
vaccin
compon
could
facilit
develop
novel
vaccin
viral
bacteri
parasit
infect
gener
potent
vaccin
conserv
protect
band
tcell
epitop
combin
highli
immunogen
epitop
deliveri
present
system
howev
combin
linear
peptid
sequenc
socal
epitop
string
suffici
linear
peptid
proven
poor
immunogen
present
conform
specif
epitop
rapidli
degrad
branch
peptid
present
practic
multipl
antigen
peptid
map
malaria
immunogen
process
manufactur
reproduc
side
promis
vaccin
approach
use
whole
sporozoit
immunogen
recent
shown
induc
protect
immun
respons
human
past
decad
develop
technolog
control
abil
peptid
protein
selfassembl
particl
welldefin
size
shape
design
mechan
chemic
stabl
nanoparticl
highli
innov
novel
approach
use
background
structur
biolog
biophys
comput
protein
design
design
epitop
string
selfassembl
socal
selfassembl
protein
nanoparticl
sapn
first
present
raman
et
al
reli
protein
chain
made
two
coil
coil
connect
short
linker
region
associ
coil
coil
forc
selfassembl
monom
roughli
spheric
nanoparticl
resembl
peptid
nanoparticl
viru
capsid
combin
strong
immunogen
effect
live
attenu
vaccin
puriti
high
specif
peptidebas
vaccin
elicit
immun
respons
potenti
sapn
serv
platform
vaccin
appar
beyond
abil
repetit
present
antigen
oppos
live
attenu
vaccin
sapnderiv
vaccin
pose
risk
infect
also
offer
signific
advantag
compar
vlp
versatil
flexibl
design
lead
better
biophys
immunolog
properti
furthermor
eas
speed
protein
express
purif
selfassembl
nanoparticl
reduc
cost
time
largescal
product
concept
success
use
design
malaria
sar
influenza
hiv
toxoplasmosi
vaccin
candid
induc
strong
antibodi
immun
respons
poorli
antigen
protein
actin
believ
sapn
technolog
display
parasit
uniqu
epitop
much
higher
percentag
per
particl
burkhard
induc
function
immun
respons
achiev
rt
contain
parasit
specif
sequenc
although
csp
demonstr
real
promis
malaria
vaccin
antigen
rt
final
implement
requir
epitop
display
formul
elicit
respons
strongli
immunogen
highli
protect
shown
sapn
platform
could
optim
display
b
cell
epitop
p
falciparum
produc
vaccin
antigen
selfadjuv
qualiti
thu
induc
potent
protect
immun
respons
without
need
heterolog
immunostimul
verifi
hypothesi
shown
true
mous
model
sapn
initi
design
display
short
peptid
band
tcell
epitop
surfac
ie
fuse
nandor
ctermini
insert
within
coiledcoil
domain
end
data
develop
laboratori
last
year
shown
sapn
vaccin
epitop
analog
rt
could
stimul
high
titer
high
avid
antibodi
present
tcell
epitop
stimul
produc
longterm
memori
tcell
result
mous
model
long
last
steril
protect
immun
respons
without
need
adjuv
howev
passiv
immun
challeng
studi
mice
use
sera
immun
primat
seem
indic
adjuv
may
need
immun
primat
adjuv
result
complet
protect
mice
unpublish
result
design
clone
express
purifi
refold
differ
sapn
construct
best
design
accord
biophys
analysi
immunolog
test
found
densiti
surfac
p
falciparum
circumsporozoit
pfcsp
bcell
epitop
trimer
coiledcoil
arm
optim
epitop
display
least
possibl
end
trimer
arm
sapn
mice
show
antibodi
produc
long
last
protect
one
year
high
affin
work
induct
classic
pathway
complement
c
demonstr
sapn
platform
highli
flexibl
amen
immunolog
engin
vaccin
design
purpos
engin
sapnscaffold
contain
univers
pan
allel
dr
epitop
padr
incorpor
coiledcoil
domain
nanoparticl
core
would
provid
tcell
help
bcell
product
antibodi
pentamer
coil
coil
arm
show
could
attach
least
differ
tcell
epitop
nterminu
chain
coiledcoil
protein
sapn
padr
induc
high
titer
antibodi
without
need
adjuv
make
sapn
construct
contain
p
vivax
csp
repeat
peptid
pfcsp
tcell
epitop
abl
demonstr
pfcsp
tcell
epitop
incorpor
within
sapn
could
induc
protect
immun
respons
pfcsp
bear
sporozoit
furthermor
delay
tapassist
process
sapnencapsul
gold
particl
earli
endosom
compart
antigenpres
cell
suggest
crosspresent
antigen
occur
explain
induct
tcell
respons
induc
intern
antigen
three
pfcsp
tcell
epitop
process
induc
longterm
central
memori
cell
time
develop
method
refold
sapn
monom
contain
much
longer
peptid
chain
shown
even
fulli
fold
protein
mw
includ
complex
cystein
disulfid
cross
link
pattern
fold
correctli
result
breakthrough
abl
transit
sapn
multiepitop
array
platform
display
larger
protein
p
falciparum
celto
conform
recogn
conform
specif
monoclon
antibodi
unpublish
data
transit
sapn
platform
simpl
sequencebas
display
system
structur
conform
base
nanoparticl
critic
develop
technolog
viabl
wide
success
vaccin
platform
recent
construct
contain
p
falciparum
csp
epitop
pipelin
human
clinic
trial
earli
